| Literature DB >> 33395751 |
Lifeng Ding1, Minxiao Jiang1, Ruyue Wang1, Danyang Shen1, Huan Wang1, Zeyi Lu1, Qiming Zheng1, Liya Wang1, Liqun Xia1, Gonghui Li2.
Abstract
Noncoding RNAs are transcribed in the most regions of the human genome, divided into small noncoding RNAs (less than 200 nt) and long noncoding RNAs (more than 200 nt) according to their size. Compelling evidences suggest that small noncoding RNAs play critical roles in tumorigenesis and tumor progression, especially in renal cell carcinoma. MiRNA, the most famous small noncoding RNA, has been comprehensively explored for its fundamental role in cancer. And several miRNA-based therapeutic strategies have been applied to several ongoing clinical trials. However, piRNAs and tsRNAs, have not received as much research attention, because of several technological limitations. Nevertheless, some studies have revealed the presence of aberration of piRNAs and tsRNAs in renal cell carcinoma, highlighting a potentially novel mechanism for tumor onset and progression. In this review, we provide an overview of three classes of small noncoding RNA: miRNAs, piRNAs and tsRNAs, that have been reported dysregulation in renal cell carcinoma and have the potential for advancing diagnosis, prognosis and therapeutic applications of this disease.Entities:
Keywords: MicroRNA; Piwi-interacting RNA; Renal cell carcinoma; Small noncoding RNA; TRNA-derived small RNA
Year: 2020 PMID: 33395751 DOI: 10.1016/j.tranon.2020.100974
Source DB: PubMed Journal: Transl Oncol ISSN: 1936-5233 Impact factor: 4.243